Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 3 6Phase 1 5Phase 1/2 3Phase EARLY_PHASE1 1

Status

Unknown 3Recruiting 2Enrolling by invitation 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 6

Conditions

Prostatic Neoplasms 53Lymphoma 44Lymphoma, Large B-Cell, Diffuse 35Lymphoma, Follicular 31Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Lymphoma, Non-Hodgkin 22Multiple Myeloma 19Leukemia 17Burkitt Lymphoma 13Hodgkin Disease 12Lymphoma, Mantle-Cell 10Neoplasms 8Lymphoma, Large-Cell, Immunoblastic 8Lymphoma, B-Cell, Marginal Zone 8Lymphoma, Large-Cell, Anaplastic 7Neoplasms, Plasma Cell 6Neoplasm Metastasis 6Lymphoma, T-Cell, Peripheral 6Recurrence 4Leukemia, Lymphocytic, Chronic, B-Cell 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pain 3Lymphoma, B-Cell 3Prostatic Neoplasms, Castration-Resistant 2Prostate Cancer Metastatic 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Myasthenia Gravis 2Leukemia, Biphenotypic, Acute 2Disease 2

Interventions

Vincristine 7Cyclophosphamide 710-propargyl-10-deazaaminopterin 7Prednisone 6Doxorubicin 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5romidepsin 3belinostat 3Gemcitabine 3liposomal doxorubicin 2duvelisib 1Vitamin B 12 1MLN 8237 1Folic Acid 1Etoposide 1E7777 fusion protein 1Decitabine 1CHOP protocol 1Brentuximab Vedotin 1Bendamustine Hydrochloride 1BAEC protocol 1Alemtuzumab 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, T-Cell, Peripheral × Prednisone × Clear all
NCT07258680 2025-12-02

BrEto-TCL

N.N. Petrov National Medical Research Center of Oncology

Phase 3 Enrolling by invitation
114 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT06072131 2025-10-23

CRESCENDO

Acrotech Biopharma Inc.

Phase 3 Recruiting
504 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT06947967 2025-09-15

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

Chipscreen Biosciences, Ltd.

Phase 3 Recruiting
224 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT03952572 2019-05-16

Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma

Peking University

Phase 3 Unknown
244 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT03553537 2018-06-12

Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Southwest Hospital, China

Phase 3 Unknown
100 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT03023358 2017-01-18

Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients

Nanfang Hospital, Southern Medical University

Phase 3 Unknown
174 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡